| Events
Column |
|
| 11/12
- 11/14 2008 National SBIR Conference.
Connecticut Convention Center, 100 Columbus Boulevard,
Hartford. more |
|
| 11/13
3:30 pm - 6:30 pm.
CURE/Yale BioHaven Special Panel: "Unexpected Outcomes:
Navigating Scientific and Management Landmines." Anlyan
Center, 300 Cedar Street, New Haven. more |
|
| 11/21
9:30 am - 5:00 pm. 10th Annual Skirball Institute Symposium:
"Inflammation & Host Defense." Farkas
Auditorium, NYU Langone Medical Center, 540 First Avenue,
New York, NY. more |
|
| 12/2
5:00 pm - 5:45 pm. CURE Annual Meeting. 300 George Street,
New Haven. Watch for details. |
|
| 12/2
5:45 pm - 7:30 pm. CURE Holiday Party. 300 George Street,
New Haven. Watch for details. |
|
| 3/25
3:30 pm - 6:30 pm. CURE/Yale BioHaven: CellDesign. Anlyan
Center, 300 Cedar Street, New Haven. more |
|
| 4/23
3:30 pm - 6:30 pm. CURE/Yale BioHaven: Cara Therapeutics.
Anlyan Center, 300 Cedar Street, New Haven. more |
|
| 5/6
3:30 pm - 6:30 pm. CURE/Yale BioHaven: Affomix. Anlyan
Center, 300 Cedar Street, New Haven. more |
|
|
Obama
Victory Bolsters Stem Cell Initiative as 2009 Legislative
Session Looms
From
the desk of Paul Pescatello, President and CEO of CURE
 The
focus of the 2009 Connecticut legislative session will be
the budget. The January to June session will be
difficult and contentious as lawmakers contend with a $300
million deficit in the context of a deteriorating state and
national economy.
As lawmakers seek to bolster revenues, we
will be diligent in making the case for Connecticut
biopharma economic development.
For
the full story |
|
Humacyte
Opens New CURE/Yale BioHaven Season
Scientists and business people gathered in Yale's Anlyan Center October 16 to hear the opening seminar of this
sea son's CURE/Yale BioHaven Entrpreneurship Series, a presentation by
Humacyte, Inc. Jon Soderstrom, managing director of Yale's Office of Cooperative Research, introduced Dr. Laura
Niklason, M.D., Ph.D., Founder and CSO. and Geoffrey Erickson, Ph.D., President and CEO, of
Humacyte.
For
the full story |
|
Cara
Therapeutics Biggest Q3 Venture Capital Stake
The largest single venture
capital investment in Connecticut in the third quarter of
2008 went to Shelton-based biotech Cara Therapeutics, according to
the MoneyTree™ report from PricewaterhouseCoopers and the
National Venture Capital Association, based on data provided
by Thomson Reuters.
For
the full story |
|
Massachusetts Sales Environment Ranked Last
The National Association of Pharmaceutical Sales Representatives
(NAPSRx®) has ranked Massachusetts as the worst state for pharmaceutical sales and marketing. The ranking follows the state's passage of a Healthcare Industry Transparency Law.
This risks exposure of product development plans to competitive firms, the
NAPSRx® maintains.
For
the full story |
|
CURE
Member News Digest
 454
Life Sciences launches
GS FLX Titanium Series
Bayer
HealthCare reports approval of Kogenate®
prophylaxis
Boehringer
Ingelheim surbey on Parkinson's care
Bristol-Myers
Squibb reports positive BARRACLUDE® results
CellDesign
subject of feature article
CGI
and Genentech agree on therapeutics
GlaxoSmithKline
to acqute BMS Egyptian business
Hartford
Hospital first with new breast cancer treatment
Ipsogen in
pact with Quest Diagnostics
Johnson
& Johnson reports new schizophrenia option
Neurogen reports
positive results for aplindore
Pfizer
says SPIRIVA®
shows sustained lung function improvement
Rib-X
Pharmaceuticals CEO named to CT Women's Hall of
Fame
UConn
Health Center sees bacteria role in MS
Yale
describes mTOR biological "traffic signal"
For
the full story |
|
